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Abstract
The adipocyte derived hormone leptin is known for its pivotal role in the  
regulation of a variety of physiological functions mainly associated with  
metabolism and energy homeostasis. One of the major functions of leptin is pertain 
with its angiogenic induction in support of organ development as well as under 
pathological conditions such as atherosclerosis and cancer. Leptin is a well-known 
pro-angiogenic growth factor which exerts its role through Ob-R receptor present on 
endothelial cells. The therapeutic application of leptin is based on its potential to 
maintain various functions at pathological conditions. In this book chapter, the 
multi-diversity potentials of leptin are discussed in detail.
Keywords: Leptin, obesity, angiogenesis, tumor progression,  
multi-signaling pathways
1. Introduction
Leptin is a 16 kDa non-glycosylated protein derived from adipose tissue, primarily 
by adipocytes. Leptin is a well-known mediator for food intake and weight loss [1]. 
Leptin mediates its functions mainly through the receptor located in the hypothalamus 
and activates signaling cascades associated with energy intake [2]. It circulates through 
the bloodstream, engages with normal metabolism, regulates energetic homeostasis, 
reproductive system, and influences the circadian cycle, lipid inflammation, and 
carbohydrate mechanisms. Leptin is well known for its pro-angiogenic potential and 
operates multiple signaling agencies through the receptor located in endothelial cells 
[3, 4]. Leptin is also secrets by other organs, such as the placenta, bone marrow, ova-
ries, stomach, and cellular structures, including mammary epithelial cells, P/D1 cells, 
and gastric chief cells [1]. Research has demonstrated that leptin plays a crucial role in 
maintaining the normal physiology of various vital systems such as the reproductive 
system and could balance cell proliferation (Figure 1). The pleiotropic hormone also 
could repair tissue damage and can prevent on-adipocyte lipotoxicity. Though leptin 
is highly acceptable for its protective mode of action, increased leptin level is often 
observed in several inflammatory conditions [5]. Hence, a therapeutic approach based 
on leptin and receptor has become the need of the hour to balance many inflammatory 
diseases in the human body. The particular book chapter provides an insight into the 
multi-diversity properties of the pleiotropic hormone leptin.
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2. Leptin synthesis and regulation
Leptin derives from adipose tissue’s obese gene (OB) transcription product [6]. 
The OB gene function was first identified in the ob/ob obese mice model and is 
located on chromosome 7 (7q31.3) and has three exons and two introns (18 kb) [7, 8]. 
Leptin receptors are located on chromosome 1 (1p31) and are noted with 17 introns 
and 18 exons and encode two proteins of 166 and 1162 amino acids, respectively [9]. 
Leptin receptors are highly expressed in the hypothalamus, cerebellum, and other 
tissues associated with the vasculature, stomach, and placental organs [10]. Leptin 
receptors have five spliced isoforms, the longest form expressed in neuronal tissue 
and the short forms expressed almost in all tissue types [11]. Leptin receptors (OB-R) 
are structurally similar to the class I cytokine family receptors. Alternative splicing of 
leptin receptor RNA results in various isoforms, designated as OB-Ra, OB-Rb, OB-Rc, 
OB-Rd, OB-Re, and OB-Rf. They all have an extracellular domain of more than 800 
amino acids, a transmembrane domain of 34 amino acids, and a variable intracel-
lular domain. The pleiotropic biological effects of leptin are explained based on the 
wide distribution of leptin receptors in humans [5]. Leptin bind to its hypothalamic 
receptors (Ob-Rs) in the brain and activates appetite and satiety. The concentration 
of leptin in plasma depends on the person’s dietary behavior, gender, and physical 
activities. The other hormonal constituents, such as insulin, estrogen, and glucocor-
ticoids, can also influence the regulation mode and the level of leptin in the blood 
[12, 13]. On the other hand, low energy or fasting, thyroid hormones, androgens, 
inflammatory cytokines, and adrenergic agonists can inhibit leptin secretion [14].
3. Leptin signaling pathways
Leptin mediates its biological effects by binding to its various alternatively spliced 
isoforms receptor located at the brain and peripheral tissues. The binding of leptin to 
Figure 1. 
Leptin exerts its pleiotropic impact on various organs. It maintains muscle tone and regulates cardiac function. 
Leptin regulates food intake and body weight management through binding with receptor located at brain. 
In the thyroid gland, leptin stimulates the secretion of TSH. In the female reproductive system, leptin manage 
menstrual cycle and supports in embryo implantation. Leptin inhibits insulin secretion and maintains blood-
glucose level. Leptin induces sprouting of new vessels from existing ones and enhances ECs proliferation and 
migration and also it regulates bone metabolism and density.
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its long-form of receptor activates various intracellular signaling pathways, including 
insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K), Janus kinase 2 
(JAK2)/Signal transducer, and activator of transcription 3 (STAT3), SH2-containing 
protein tyrosine phosphatase 2 (SHP2)/Mitogen-activated protein kinase (MAPK), 
and 5′ adenosine monophosphate-activated protein kinase (AMPK)/acetyl-CoA 
carboxylase (ACC) [8]. The binding of leptin to its receptor activates JAK2, which in 
turn phosphorylates the Tyrosine amino acid residues in LepRb and is terminated by 
a suppressor of cytokine signaling 3 (SOC3) [15].
Leptin input a significant role in energy homeostasis and neuroendocrine 
function through JAK2/STAT3 signaling pathway. A selective deletion in LepRb or 
STAT3 in LepRb-expressing neurons ends with obesity and hyperphagia, which 
further supports the dominant role of the JAK2/STAT3 signaling pathway in the 
leptin-induced body weight regulation [16]. One interesting fact about leptin and 
insulin is that both have similar intracellular signaling pathways (PI3K/Akt) in 
neurons [17]. The ERK, a member of the MAPK family, acts downstream of LepRb 
and is mediated through SHP2 or by JAK2. Inhibition of ERK prevents leptin-based 
sympathetic function in brown adipose, which further supports SHP2/MAPK 
in leptin energy expenditure and food intake [18]. Leptin’s suppressive mode of 
action on food intake initiates by inhibiting the effect of AMPK in the brain. The 
inhibition of AMPK regulates feeding through the mTOR (mammalian target of 
rapamycin)/s6Kinase pathway [19]. In skeletal muscle, leptin directly exists its 
effect through AMPK signaling and stimulates fatty acid oxidation and glucose 
uptake [20]. Leptin has a prominent role in the modulation of both innate and adap-
tive immunity. It stimulates neutrophil chemotaxis and promotes phagocytosis of 
macrophages through the receptor binding mechanism. It is also known to increase 
the production of IL-6 and TNF-alpha under pathological conditions [21]. Leptin 
protective action on neutrophils exerts through PI3K and MAPK depending on sig-
naling and prevents apoptosis of neutrophils. Leptin via STAT3 activation promotes 
Figure 2. 
Leptin regulates many signaling pathways through receptor (Ob-Rb) binding mechanism. It regulates gene 
expression through JAK/STAT3 pathway, modulates other signals through PI3K/rho family dependent pathway, 
induces vasodilation through NO-dependent pathway, and accelerates angiogenesis through PI3K/Akt/mTOR/
s6 kinase/VEGF a and PI3/Akt/NO-dependent pathways. Promotes tumor progression through HIF-1 alpha 
pathway and enhances platelet aggregation through the PLC pathway. The SOS3 molecule function as a 
regulator of leptin induced signaling activations by negative feedback mechanism.
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natural killer cell activation [22]. In the adaptive immune response, leptin promotes 
native T cells proliferation by increasing the expression of interferon-gamma and 
TNF-alpha in T cells [23].
Apart from the mentioned direct signaling pathways, leptin interacts with many 
signaling functions as a multifunctional cytokine. Leptin shows a potential func-
tional relationship with Nitric Oxide (NO) and favors NO-mediated lipolysis and 
vascular tone [24]. The significant other functions of leptin are associated with its 
predominant role in angiogenesis. It is observed that Endothelial cells (ECs) express 
OB-R leptin receptors and the binding of leptin to OB-R enables the growth of small 
blood vessels [3]. Recently, it has been identified that leptin could induce PI3K/Akt/
mTOR/s6Kinase signaling pathway and enhance VEGF mRNA’s transcription level 
while inducing angiogenesis [4]. One of the intriguing possibilities of leptin is that 
it promotes neovascularization through paracrine mode concerning the volume of 
fat mass [25]. Leptin could promote proliferation in colonic epithelial cells in vitro 
conditions. Moreover, the presence of OB-R receptor in human colon cancer cell 
lines and human Colonia tissue thus supports the angiogenic role of leptin under 
cancer environment through PI3K/AKT, MAPK/ERK, and JAK2/STAT3 pathways 
[26, 27]. Leptin could induce apoptosis and regulate actin-myosin cytoskeleton 
associated with Rho family GTPases (Figure 2) [28].
4. Leptin as an energy balancer
Leptin acts in the brain and maintains energy homeostasis through a negative 
feedback mechanism [29]. The process is mediated through the receptors in the 
hypothalamic area named the paraventricular nucleus, ventromedial hypothalamic 
nucleus, lateral hypothalamic area (LHA), and arcuate nucleus (ARC). The ARC is the 
primary site for leptin to integrate peripheral energy balance signals [30]. Recently, it 
has been observed that leptin could play a significant role in the long-term regulation 
of energy balance and short-term management of body weight and food intake. The 
gastric leptin produced because of the actions of the intestinal peptide serves as a local 
stimulus and plays a vital role in food digestion and absorption [31]. The particular 
area requires more investigations to prove the role of gastric leptin in food digestion 
and absorption. Research supported the predominant role of leptin in neuroendocrine 
mediated starvation through changing sympathetic nervous system activity [32].
Overweight or obesity is characterized by increased fat mass and is proportional to 
circulating leptin levels in individuals [33]. The elevated levels of leptin in body fluid 
are explained based on leptin resistance. The hypothesis was proved using rodents 
fed with a high-fat diet and leptin sensitivity loss in ARC neurons [34]. At the cel-
lular level, the inflammatory signals mediate the process of leptin resistance. The two 
significant characteristics of obesity connect with hyper-leptinemia and leptin resis-
tance. At the molecular level, the leptin gene is over-expressed in overweight or obese 
individuals [35]. Apart from these functions, many researchers reported the genetic 
and epigenetic factors that control leptin action in energy homeostasis and food intake 
[36–38]. A better understanding of leptin-induced pathogenicity of obesity and 
obesity-related disorders and the regulation of energy homeostasis will provide an 
alternative solution in preventing obesity and obesity-related co-morbidities.
5. Leptin as an immune modulator
Despite nutritional regulation, leptin has gained more attention for its pivotal 
role in inflammation. The innate immune system plays a major role in the regulation 
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of leptin production. Leptin responds to immune cells and its receptors, expressed 
by most cells, and activates pro-inflammatory features in the host [39]. Leptin 
plays an essential role in T cell development, and leptin deficiency directly impacts 
the levels of circulating T cells [40]. Many studies supported the role of leptin in 
immunity modulation and mentioned the signaling pathways related to the notion 
[39, 41, 42]. Leptin could accelerate the proliferation process in native CD4+T cells 
and favored by reducing the levels of IFN from T cells [43, 44]. During the wound 
healing process, leptin activates both inflammatory and proliferative phases in 
favor of tissue repair [45]. The increased plasma leptin level acts as an indicator of 
leptin-induced inflammatory response at the injury site. These exciting features of 
leptin gained attention as a pro-angiogenic molecule in ischemic tissues [46]. Leptin 
induces monocyte chemoattractant protein1 (MCP1) expression [47].
Leptin plays a vital role in producing GM-CSF and G-CSF and activating hemato-
poietic cells in humans [48]. In animal models, up-regulation of leptin has been found 
in acute inflammation states. But, experimental evidence from rodents does not match 
with human studies [49]. Leptin plays a significant role in basophils and eosinophils 
functions and acts as a chemoattractant [50]. Leptin is abnormally expressed in auto-
immune diseases, particularly in skin disorders [51]. Obesity decorates skin normal 
physiology such as keratosis pilaris, tags, and striae diseases and increases the levels 
of pro-inflammatory cytokines and adipokines, including leptin [52, 53]. In the event 
of inflammation, leptin increases the release of Nitric Oxide and activates the macro-
phages and neutrophils, and increases natural killer cells’ activity (NK) [54]. Leptin 
up-regulates the cytokines production and phagocytic function in obese conditions 
[55]. It balances monocytes and activations markers and directly involves in interleu-
kin1 and cyclooxygenase expression [56]. One of the prominent roles of leptin pertains 
to maintaining the balance between the immune system and metabolism regulation. 
Under malnutrition state, leptin acts as an immunosuppressive factor [42].
6. Leptin as a pro-angiogenic factor
In 1998, Sierra-Hongmans reported that vascular endothelial cells express leptin 
receptors, especially the long-form. This discovery leads to an insight into the role of 
leptin in angiogenesis [57]. The angiogenic impact of leptin was conformed used on 
in vitro and in vivo models analysis [3, 58]. Jin et al. proved that leptin could induce 
angiogenesis in the cornea of the Zucker obese rat model through the activation of the 
Ob-R gene [59]. Leptin exerts a paracrine mode of action in tissues and activates vari-
ous signaling during the promotion of angiogenesis. This endocrine hormone activates 
Akt signaling pathway and mediates NO-induced vasodilation [60]. In endothelial cell 
migration, leptin signals through the ERK pathway and activates the PI3k, Akt, and 
eNOS molecules. By stimulating the local neovascularization in adipose tissue, leptin 
promotes its release into the vascular system. This process enhances fatty acid oxida-
tion and supports maintaining a proper balance between adipose tissue’s fat deposits 
and blood supply [61]. Even though the vascular fenestration capacity of leptin is 
poorly understood, the effect is found similar to VEGF [62]. Leptin plays a crucial role 
in exchanging nutrients between the fetus and maternal circulation in the placenta via 
enhancing vascular permeability and could induce angiogenesis in the placenta [61].
7. Leptin and pathogenesis
Leptin does not only imply energy homeostasis but also extends its regula-
tory function at infectious conditions. But the contagious status regulation mode 
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of leptin is the least explored signaling mechanism. Latest research support that 
leptin could activate phagocytosis of macrophages and could secure the immune 
cells from pathogenic infections [63]. In Klebsiella pneumonia infection, exogenous 
administration of leptin shows CD11b dependent phagocytosis [64]. It protects 
lymphocyte deficient mice from various conditions [65]. Several studies have 
strongly highlighted the therapeutic application of the molecule to innervate infec-
tious diseases, including AIDS [66].
8. Leptin resistance with disease
However, under certain conditions, like obesity, leptin levels decrease in associa-
tion with leptin resistance. But it is still unclear how the leptin resistance mechanism 
is exerted throughout the tissue. So far, studies have suggested leptin resistance with 
metabolic process and revealed a defect in the Ob-R leptin receptor gene [67]. Up to 
date, the leptin resistance mechanism has been categorized as follows: gene muta-
tion specific to the leptin structure, defect in the transport of leptin through the 
blood–brain barrier, and malfunctions of leptin receptors. Among these, mutations 
are rare in humans, occurring in substitution of guanine by adenine at the donor 
splice site of exon 16 of the leptin gene [68]. Second, the brain’s blood vessels usu-
ally express leptin receptors and transport leptin into the cerebrospinal fluid. But 
excessive levels of leptin in the bloodstream decrease the permeability of BBB, thus 
develops leptin resistance [69]. Finally, the serum level of leptin significantly affects 
the transcriptional level of the OB (ob) gene and the equilibrium of leptin secretion 
in adipose tissue. In such cases, these dramatic changes promote leptin resistance 
until leptin level remains standard in the bloodstream. These changes have been 
widely observed in obesity [70].
Furthermore, several stimuli affect leptin resistance, including the circadian 
cycle. Interestingly, leptin also develops its leptin resistance, observed in diet-
induced obesity [71]. This leptin resistance also provides an environment for the 
accumulation of immune response against pathogens, particularly high-fat diet-
induced inflammation, which activates inflammatory cytokines [72]. But, in-depth 
leptin resistance mechanisms need much more attention.
9. Leptin role in disease conditions
9.1 Metabolic syndrome and obesity
Fat tissue is an energy storage tissue that functions as a negative feedback loop in 
energy homeostasis [73]. Homozygous mutation of leptin causes extreme obesity, 
diabetes and suppresses glucose metabolism in insulin-deficient diabetes [8]. The 
ob/ob mice model has relatively higher food intake and observed a larger volume of 
lipid accumulation in the liver than the control group [74]. It has been assumed that 
nearly 95% of individuals have resistance against leptin [75]. The type 2 diabetes 
condition is noted with an increased level of leptin and suggested using leptin as a 
biomarker to study the effect of obesity in diabetes-related morbidities [76]. Some 
studies also reported that higher leptin levels are associated with the risk of heart-
related problems in obese individuals [76, 77]. In younger adults, elevated leptin 
levels are positively correlated with HOMA-IR and BMI index [78].
Development of severe early-onset obesity and hyperphagia are common in 
people with homozygous LEP mutation [79]. Replacement of leptin from a thera-
peutic viewpoint has improved insulin sensitivity and thus proved the role of leptin 
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in metabolic disorders, including T2DM. In humans, serum leptin level is positively 
correlated with the percentage of body fat, fat mass, size of adipocytes, and BMI 
[80]. Obesity connected with the enlargement of adipose cells enhances the serum 
leptin level, which further results in the progression of chronic hyperinsulinemia. 
The majority of obese patients are hyper leptinaemic which supports the develop-
ment of hypertension, metabolic syndrome, and cardiovascular diseases [81]. 
Mutation in the leptin receptor located at the hypothalamus alters the transport of 
leptin across the blood–brain barrier. This incidence increases the level of serum 
leptin and hence diet-induced obesity. Obesity connected with the leptin receptor 
mutation is linked with insulin resistance and in the development of T2DM [82].
9.2 Cardiovascular diseases
The level of leptin could influence the function of the heart. It could lead to the 
progression of many heart-related problems such as coronary artery disease, stroke, 
chronic kidney disease (CKD), peripheral artery disease (DAP), carotid plaque 
instability [83]. It was observed that elevated level of serum leptin in obese patients 
contributes to the low-grade systemic inflammation in favor to develop cardiovascu-
lar disease. Moreover, a high level of leptin is used as a biomarker to measure the pro-
gression of heart failure in patients with dilated cardiomyopathy [84]. On the other 
hand, many studies using rodent, obese and diabetic models highlighted the benefi-
cial impact of leptin on cardiac metabolism through glucose metabolism and fatty 
acid oxidation. This evidence suggested that leptin compensates for cardiac insults 
due to ischemia and heart failure [85]. Leptin signaling in the modulation of heart 
function is studied extensively using animal models. These studies demonstrated 
that impaired cardiac leptin signaling majorly reflects in metabolic inflexibility for 
glucose utilization, defects in cardiac contractibility, impaired recovery of cardiac 
function due to coronary artery ligation [86, 87]. Clinical data cemented that plasma 
leptin levels are associated with LV hypertrophy and increased myocardial wall 
thickening [88]. Leptin also increased the blood pressure level in obese individuals 
with a loss-of-function mutation in leptin or leptin receptor [89]. Thus, a leptin-
mediated increase in blood pressure directly increases the heartbeat rate, developing 
into cardiac hypertrophy through the sympathetic nervous mechanism [90].
Leptin-mediated aldosterone synthesis impairs myocardial relaxation and con-
tributes to cardiovascular diseases through a novel mechanism associated with endo-
thelial dysfunctions [91]. Increased plasma leptin levels positively correlate with the 
number of stenotic coronary arteries in patients with coronary artery disease [92]. In 
vitro analysis using HUVEC cells demonstrated that leptin induces chronic oxida-
tive stress in ECs and contributes to vascular pathology development [93]. Also, the 
cytokine hormone leptin could stimulate vascular smooth muscle cells proliferation 
and migration, thereby increasing calcification and vascular lesions [94]. Altogether, 
it was suggested that hypertension, obesity, and endothelial dysfunctions are more 
frequent in T2DM patients with elevated leptin levels [95].
9.3 Tumor progression
Cancer progression is a complex process that includes the interaction between 
ECs, fibroblast, insusceptible cells, and adipocytes [96]. Normal epithelial cells do 
not express leptin and leptin receptors but are overexpressed in a cancerous envi-
ronment. Leptin enhances the survival rate of cancer cells through the activation 
of a downstream signaling molecule known as sirtuin-dependent NAD-dependent 
deacetylase 1 (SIRT 1) [97]. Leptin can activate many signaling pathways in 
cancer directly by activating TNF alpha, IL-6, ROS, VEGF, MMP2, and MMP9. 
Leptin
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It can also support tumor growth by activating JAK/STAT, Akt, FGF2, and NO 
molecules through receptor (Ob-R) binding mechanisms in ECs [98, 99]. The 
appetite hormone can potentially interact with pre-neoplastic or cancerous breast 
epithelium in a breast cancer environment. Leptin secreted by the breast cancer 
surroundings inhibits inflammatory cytokines and thus blocks macrophages’ 
production [100, 101]. The cytokine enhances neovascularization through VEGF 
in many cancerous conditions [102, 103].
Increased levels of serum leptin and insulin under obese conditions cause 
colorectal cancer [104]. Leptin supports the proliferation and invasiveness of 
colonic cells. Leptin receptors are found to express in human colon cell lines and 
are believed to initiate cancer angiogenesis. Hyperlipidemia and insulin resis-
tance can cause low-grade systemic inflammation that promotes proliferation 
and angiogenesis and inhibits apoptotic rate in colon cancer [105]. Leptin and 
its receptors express in papillary thyroid tumors and enhance the pathogenicity 
through PI3K/Akt pathway [106].
Obesity enhances the concentration of leptin around the pancreatic carcinogenic 
environment. The enhanced concentration of leptin favors vascularization, migra-
tion, and invasiveness of pancreatic tumor cells [105]. Leptin has a crucial role in 
developing the non-alcoholic fatty liver disease (NAFLD) via insulin resistance. This 
imbalance ultimately worsens hepatic inflammation and results in the development 
of liver fibrosis [107]. The receptor Ob-R identified in Kupffer cells (KC), and binding 
of leptin with receptor enhances the expression of TGF beta, TIMP1 in liver fibrosis 
scenario [108]. However, the direct role of leptin in liver cancer is controversial, with 
some reports suggesting its role in liver cancer. In contrast, others offer its inhibitory 
potential on tumor size in hepatic cancer [109, 110]. The level of leptin was found to 
decrease in patients with cancer cachexia compared to non-cancer cachexia [111].
10. Leptin therapeutics past and future
The significant need for clinical implications of leptin is to regulate the regu-
lar physiological role of leptin in pathological conditions. There is a correlation 
between body weight loss and serum levels of leptin. As a result, several therapeutic 
approaches have been implemented for the use of leptin in obesity control. However, 
increased resistance to leptin is also a significant issue in the treatment of obesity. But, 
a combination of therapeutic approaches may be helpful to these problems [112, 113].
Among the adipocyte secreted hormones, leptin is the front that has been 
used for the treatment of hypoleptinemia status clinically. The most important 
therapeutic benefits of leptin are rely on providing a novel method for treating the 
conditions connected with mutation of leptin gene and lipodystrophy in humans 
[114]. Treatment with exogenous leptin in obese patients concluded that leptin can 
decrease the body weight and fat tissue of the subjects [115]. It was also noted that 
leptin excerpts a dose-dependent regulating potential as individuals energy intake 
and appetite [116, 117]. Development of leptin analogous with full biological effect, 
especially with the potential to cross the blood–brain barrier, can improve the 
results obtained from leptin therapy focusing on obesity management. The admin-
istration of leptin can accelerate wound healing in diabetic ob/ob and wild-type 
mice in a dose-dependent manner through leptin receptor mediation [118].
Exogenous administration of leptin can regulate fatty acid oxidation in muscles 
and control triglyceride synthesis in the liver [119, 120]. Even though the mecha-
nisms in humans are not clear, administration of leptin and adiponectin was found 
to improve insulin resistance in type 2 diabetic conditions [121, 122]. The immune-
modulatory impact of exogenous leptin administration in rodents highlighted that 
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the cytokine could activate encephalomyelitis [123]. Various in vitro assays also 
supported the immune stimulator action of leptin [124, 125]. Identifying high-
affinity-binding molecules to control the level of circulating leptin is suggested as an 
advanced therapy for treating arthritis and inflammatory bowel disease. In addition, 
replacement with recombinant methionyl human leptin is a brilliant choice for 
treating pathological conditions associated with relative or absolute leptin deficiency 
and restoring immune functions [126]. One of the future therapeutic approaches of 
leptin relies on its use as a natural adjuvant in vaccinations since it can stimulate T 
helper I responses while down-modulating regulatory T cells [127].
Considering the cancerous conditions, ATLO-ACA, an Ob-R antagonist peptide, 
finds effective for treating triple-negative breast cancers in experimental models 
[128]. Also, therapy based on leptin/Ob R axis function inhibition was identified 
as adjunctive therapy for newly diagnosed and recurrent glioblastoma [129]. The 
modern therapeutic approaches of leptin are connected with molecular approaches 
at gene levels are 1) CRISPR-Cas 9 connected with floxed leptin-locus based 
approaches - to lower the leptin levels, 2) Cre-lox P- generation of one copy of Lep 
eliminates – to lower the leptin levels, glucose and insulin tolerance, c) administra-
tion of neutralizing leptin-specific antibodies –to reduce the circulating levels of 
leptin to reduce food intake and hepatic stenosis [130]. Administration of human 
recombinant leptin accelareated dose-dependent sprouting angiogenesis and 
hypothesized that the application of human recombinant leptin could improve the 
wound healing process through neovascularization [3]. So far, evidence gathered 
from previous studies highlights the role of leptin in therapeutic applications. But 
overcoming leptin resistance is a significant challenge in leptin-based therapy.
11. Conclusion
In conclusion, leptin is considered an essential pleiotropic adipokine with 
various effects on biological systems. However, leptin’s structural and functional 
characteristics and its receptors are characterized by a unique signaling mechanism. 
Focusing on leptin could be a therapeutic approach to manage autoimmune inflam-
mation associated with obesity, cancer, and metabolic diseases. But further research 
is needed to understand the relationship between leptin on biological systems, as it 
has complex signaling mechanisms.
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